Colorectal cancer - molecular basis to targeted therapeutics.

结直肠癌 - 靶向治疗的分子基础。

• 批准号: nhmrc : 487922
• 负责人: A/Pr Joan Heath
• 金额: $ 1321.49万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Programs
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/colorectal-cancer-molecular-targeted-therapeutics/97922
• 关键词: Colorectal; cancer; molecular; basis; targeted

Cancer of the colon and rectum is the most common form of cancer in Australia. Over 12,000 people are diagnosed each year with colorectal cancer (CRC) and more than one third of people will die of their disease. CRC is caused by mistakes in production of colon cells. Our research aims to discover new ways to detect CRC, develop smart drugs and nanoparticle delivery systems for destroying all types of CRC cells. We will then test our new anti-cancer drugs in clinical trials with CRC patients.

结肠癌和直肠癌是澳大利亚最常见的癌症。每年有超过 12,000 人被诊断患有结直肠癌 (CRC)，其中超过三分之一的人将死于该病。 CRC 是由结肠细胞生产过程中的错误引起的。我们的研究旨在发现检测结直肠癌的新方法，开发智能药物和纳米粒子递送系统来破坏所有类型的结直肠癌细胞。然后我们将在结直肠癌患者的临床试验中测试我们的新抗癌药物。